Antibiotic Releasing Biodegradable Scaffolds for Osteomyelitis

ISSN: 1875-5704 (Online)
ISSN: 1567-2018 (Print)

Volume 12, 6 Issues, 2015

Download PDF Flyer

Current Drug Delivery

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Istvan Toth
School of Pharmacy,University of Queensland
Brisbane, 4072

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 1.478

Antibiotic Releasing Biodegradable Scaffolds for Osteomyelitis

Current Drug Delivery, 11(6): 687-700.

Author(s): Manitha Nair and Amit Krishnan.

Affiliation: Amrita Center for Nanosciences and Molecular Medicine, Amrita Institute of Medical Science & Research Center, Amrita Vishwa Vidyapeetham University, Cochin, Kerala 682041, India.


Osteomyelitis is characterized by progressive inflammatory bone degeneration. In the management of chronic osteomyelitis, it is necessary to remove the infected bone tissue followed by implantation of an antibiotic releasing biomaterial that can release antibiotic locally for long periods of time. The main carrier used in clinics for this application is polymethylmethacrylate (PMMA) (Eg. Septopal beads). However, major drawback is the need of an additional surgery to remove the beads after therapy, as PMMA is not biodegradable. This necessitates the requirement of biodegradable carrier systems that can release antibiotics and simultaneously support debrided bone formation. This review summarizes biodegradable carrier systems that have been reported for the localised treatment and prophylaxis of osteomyelitis.


Bacterial internalization, biodegradable scaffolds, osteomyelitis, staphylococcus aureus.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 11
Issue Number: 6
First Page: 687
Last Page: 700
Page Count: 14
DOI: 10.2174/1567201811666140414120002
Orphan Drugs and Rare Diseases Conference

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science